Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.

Current oncology reports - 6 Feb 2020

Wierzbicki Kyle, Ravi Karthik, Franson Andrea, Bruzek Amy, Cantor Evan, Harris Micah, Homan Morgan J, Marini Bernard L, Kawakibi Abed Rahman, Ravindran Ramya, Teodoro Rodrigo, Yadav Viveka Nand, Koschmann Carl

Abstract excerpt

PURPOSE OF REVIEW: H3K27M is a frequent histone mutation within diffuse midline gliomas and is associated with a dismal prognosis, so much so that the 2016 CNS WHO classification system created a specific category of "Diffuse Midline Glioma, H3K27M-mutant". Here we outline the latest pre-clinical data and ongoing current clinical trials that target H3K27M, as well as explore diagnosis and treatment monitoring by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cerebrospinal Fluid
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Histone Deacetylase Inhibitors

Share to Immunotherapy, Adoptive

Share to Jumonji Domain-Containing Histone Demethylases

Share to Liquid Biopsy

Share to Spinal Cord Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32030483
DOI: 10.1007/s11912-020-0877-0
PMCID: PMC7501595

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.PMID 32030483Read ↗

Liquid biopsy in H3K27M diffuse midline glioma.Semantic proximity Read ↗

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline GliomaSemantic proximity Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity Read ↗

Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.Semantic proximity Read ↗

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read ↗

H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic OptionsSemantic proximity Read ↗

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Characteristics of H3K27M-mutant diffuse gliomas with a non-midline locationSemantic proximity Read ↗

H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.Semantic proximity Read ↗

Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.